Ramesh Gadepalli, Sai Nyayapathi Venkata Balakrishna, Gururaj Pramod, Bhupal Reddy, Patel Nilesh
Department of Cardiology, Yashoda Hospital, Secunderabad, Telangana, India.
Interv Med Appl Sci. 2018 Jun;10(2):65-69. doi: 10.1556/1646.10.2018.14.
This study was aimed to determine the levels of hs-CRP, serum ferritin, and Lp(a) and to study the prevalence of metabolic syndrome (MetS) in young patients (≤45 years) with and without acute myocardial infarction (AMI).
This was a cross-sectional, case-control study conducted at a tertiary care center in India. Equal number of patients with matched age and sex ( = 51) were included in case group (with AMI) and in control group (without AMI). Subjects were assessed for the presence of MetS as per modified ATP III criteria. The hs-CRP, Lp(a), and serum ferritin were also measured.
The prevalence of MetS was found to be 62.74% in case group, whereas 33.33% in control group with decreased HDL level as the most prevalent parameter. The hs-CRP level was found to be 15.35 ± 8.27 mg/dl in case group and 1.85 ± 1.05 mg/dl in control group and Lp(a) was 33.84 ± 23.69 mg/dl in case group and 19.68 ± 10.39 mg/dl in control group. No significant difference was observed in the serum ferritin level in case (264.2 ± 40.6 ng/dl) and control (225.51 ± 45.35 ng/dl) groups.
From this study, we can conclude that the assessment of these novel risk factors [hs-CRP, Lp(a), and MetS] may be used for the risk estimation and can help to prevent future mortality and morbidity due to CVD.
本研究旨在测定超敏C反应蛋白（hs-CRP）、血清铁蛋白和脂蛋白(a) [Lp(a)]水平，并研究急性心肌梗死（AMI）患者与非AMI患者（年龄≤45岁）中代谢综合征（MetS）的患病率。
这是一项在印度一家三级医疗中心进行的横断面病例对照研究。病例组（患有AMI）和对照组（未患AMI）纳入了年龄和性别匹配的同等数量患者（各51例）。根据修改后的ATP III标准评估受试者是否存在MetS。同时还测定了hs-CRP、Lp(a)和血清铁蛋白。
病例组中MetS的患病率为62.74%，而对照组为33.33%，其中高密度脂蛋白（HDL）水平降低是最常见的参数。病例组hs-CRP水平为15.35±8.27mg/dl，对照组为1.85±1.05mg/dl；病例组Lp(a)为33.84±23.69mg/dl，对照组为19.68±10.39mg/dl。病例组（264.2±40.6ng/dl）和对照组（225.51±45.35ng/dl）的血清铁蛋白水平未观察到显著差异。
从本研究中，我们可以得出结论，对这些新的危险因素[hs-CRP、Lp(a)和MetS]进行评估可用于风险估计，并有助于预防未来因心血管疾病（CVD）导致的死亡和发病。
